Ocuphire Pharma Inc

NASDAQ:OCUP   3:59:52 PM EDT
1.95
-0.10 (-4.88%)
Products

Ocuphire Pharma Receives PDFUA Fee Waiver For Nyxol New Drug Application From FDA

Published: 09/12/2022 13:05 GMT
Ocuphire Pharma Inc (OCUP) - Ocuphire Pharma Receives Pdfua Fee Waiver for Nyxol New Drug Application From FDA.
Ocuphire Pharma Inc - Remains on Track to File NDA for Nyxol in Its First Indication, Reversal of Mydriasis (rm), in Late 2022.
Ocuphire Pharma Inc - FDA) Has Granted a Small Business Waiver of Prescription Drug User Fee Act Fee of $3.1 Million for 505(b)(2) NDA for Nyxol.